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Sleep apnea is clinically recognized as a heterogeneous group of disorders characterized by recurrent apnea and/or hypopnea. Its
prevalencerangesfrom4%to24%.Ithasbeenimplicatedasanindependentriskfactorforseveralconditionssuchashypertension,
stroke, arrhythmia, and myocardial infarction. Recently data has been emerging which suggests an independent association of
obstructive sleep apnea with several components of the metabolic syndrome, particularly insulin resistance and abnormalities in
lipid metabolism. We hereby review the salient features of the association between sleep and diabetes.
1.Introduction
Sleep apnea is clinically recognized as a heterogeneous group
of disorders characterized by recurrent apneas (complete
cessation of breathing) and/or hypopnea (decrease in airﬂow
with desaturation of 4%) [1]. It is estimated that obstructive
sleep apnea may aﬀect at least 2%–4% of the general
population, with prevalence estimates that may be much
higher based on demographic variables such as age, sex,
and body mass index (BMI) [2]. The apnea-hypopnea index
(AHI) was deﬁned as the total number of obstructive apneas
(cessation of airﬂow for at least 10 seconds) and hypopneas
(decrease of the airﬂow signal amplitude by at least 50%
accompanied by oxyhemoglobin desaturation of at least 4%
or by an arousal) per hour of sleep [3]. An AHI of 10 or
higher and excessive day-time somnolence has also been
used to deﬁne obstructive sleep apnea (OSA), ﬁnding similar
ﬁgures in a large cohort of male subjects [4]. Data from
Sleep in America poll by The National Sleep Foundation
showed that approximately 25% of adults and 57% of obese
individuals are at high risk for obstructive sleep apnea (OSA)
[5]. Sleep apnea has been implicated as an independent risk
factor for hypertension, myocardial infarction, and stroke
[6].
Diabetes Mellitus is a well-established risk factor for
cardiovascular disease. Data from the Third National Health
and Nutrition Examination survey indicate that 5.1% of
adults in the United States have physician diagnosed Dia-
betes Mellitus and an additional 2.7% meet the criteria of
diabetes but remain undiagnosed [7]. Given the pandemic of
obesity, the prevalence of Type 2 Diabetes Mellitus(DM) and
metabolic syndrome has also increased dramatically over the
last decade [8–12]. DM aﬀects approximately 6% of adults in
the United States [13] .T h e r eh a v eb e e ns e v e r a ls t u d i e sw h i c h
have suggested an independent association of obstructive
sleepapneawithseveralcomponentsofmetabolicsyndrome,
particularly insulin resistance and abnormalities in lipid
metabolism [14–17].
There has been data that long-term intermittent hypoxia
and sleep fragmentation increase sympathetic activity, which
in turn lead to disorders of glucose metabolism [18]. Alter-
natively some studies have suggested that insulin resistance
and chronic hypoxemia may in turn lead to development of
sleep apnea syndrome [19].
The Sleep Heart Health Study found that subjects with
DM had increased sleep disordered breathing and more
severe hypoxemia [20]. Factors inﬂuencing and increasing
the risk of sleep apnea include male sex [1, 21, 22], obesity
[23, 24], age [4, 25], and race [25, 26]. Studies done to look
at the association of DM as an etiologic factor for sleep
apnea have suggested that autonomic neuropathy may be
a responsible for dysfunction of central respiratory control2 International Journal of Endocrinology
of the diaphragm and decreased upper airway tone. Somers
et al. found that sleep disturbance negatively aﬀects glucose
metabolism and endocrine function. After six nights of four
hour sleep, sympathetic nervous activity has increased (P<
.02)[27].Findingsfromepidemiologicalstudiesindicatethat
sleep apnea is independently associated with hypertension
[28] and cardiovascular disease [29]. A growing body of
literature suggests that sleep apnea is associated with fasting
hyperglycemia, insulin resistance, and DM [30].
Several factors have been associated with diabetes in
sleep from obesity to altered glucose metabolism. Insulin
resistance, glucose intolerance, REM sleep and diabetes, and
the eﬀect of sleep apnea treatment on diabetes have been
implicatedascausationfactors.Wewilltrytosummarizethis
complex subject in as simple a form as possible.
2.Obesity,OSA,andDiabetes
Obesity is generally regarded as a risk factor for both OSA
and Insulin resistance [31, 32]. During the past 20 years,
the prevalence of obesity and DM in the United States has
increased consistently [33]. Obesity, in particular central
obesity, is the strongest risk factor for sleep apnea [34–
41]. OSA is prevalent particularly among middle-aged, obese
men, although its existence in women and lean individuals is
being increasingly recognized.
There is an alarming rise in the prevalence of DM
that may be largely attributed to the epidemic of obesity
[42]. The strongest risk factor for both DM and OSA is
obesity withahighvisceral(central)fatdistribution [43,44].
Approximately two thirds of all patients with OSA are obese,
and the eﬀect of obesity as a predictor of OSA is 4 times
greater than the inﬂuence of age and twice as great as the
inﬂuence of male gender [44].
Obesity, macroangiopathy, hypertension, and dyslipi-
d e m i ao f t e nc o e x i s tb o t hi nO S Aa n di nN I D D M .H o w e v e r ,
factors other than obesity appear to play a signiﬁcant role
in the development of insulin resistance and metabolic
disturbances in patients with OSA [45–50] including sleep
fragmentation, increased sympathetic activity, and intermit-
tent hypoxia [27, 51–54].
3.ObesityandInsulinResistance
TheprevalenceofoverweightandobesityintheUnitedStates
and other industrialized countries is rapidly increasing. Over
the last 40 years, the average body mass index (BMI) in men
and women aged 20–74 yrs has increased from just over
25Kg/M2 to almost 28Kg/m2 [55–57].
It is also recognized that many subjects with OSA have
central obesity and other features of metabolic syndrome
[39], which is most widely accepted as being comprised of
hyperinsulinemia, glucose intolerance, dyslipidemia, central
obesity,andhypertension[58].Insulinresistanceisincreased
with increasing levels of obesity, but the reasons for this
are not completely clear. As weight increases, the risk
to develop complications such as hypertension, insulin
resistance, diabetes mellitus, sleep disordered breathing, and
obstructive sleep apnea syndrome increases [59].
The relationship of OSA with insulin resistance [47]
may be the pathway that leads to increased risk for the
development of cardiovascular disease in some patients. It
has been observed that OSA patients have increased leptin
[60] and C-reactive protein(CRP) [61], indicating a possible
role in the pathogenesis of cardiovascular morbidity. Punjabi
et al. [62] found that CRP is associated with nocturnal
hypoxia. Thus, obesity is strongly associated with OSA [63],
insulin resistance [64], leptin [65], and CRP [66]l e v e l sa n d
may be the major confounding factor in the relationship of
OSA to insulin resistance and cardiovascular morbidity.
4. OSA andInsulinResistance
Several studies have tried to establish the association
between OSA and diabetes [67–70]. Van Cauter et al. have
shown that experimentally induced acute sleep deprivation
can cause a state of glucose intolerance [71]. OSA can
aﬀect the metabolism indirectly, by decreasing the quantity
and/or quality of sleep [5]. Insulin resistance has been
induced among healthy volunteers by sleep restriction.
Sleep restriction on the other hand has also resulted in an
increase in evening cortisol level and sympathetic activation
[72].
A number of studies have also examined the cross-
sectional relationship between OSA, as assessed by overnight
polysomnography, and metabolic abnormalities [31, 39, 48–
50, 67–69, 73–75]. Most of the studies suggest that OSA is
related to impaired glucose tolerance and insulin resistance.
Recent studies also conﬁrm the high prevalence of habitual
snoring in DM [73], or higher prevalence of metabolic
syndrome in habitual snorers [74]. Over the past decade
there has been increasing clinical and experimental evidence
of the association between insulin resistance and OSA in non
obese diabetic patients with autonomic neuropathy [75]. A
laboratory-based investigation showed that diabetic patients
with autonomic neuropathy are more likely to have OSA
and central apnea than diabetic patients without autonomic
neuropathy [76, 77].
Frequent snoring was associated with reduced glucose
tolerance,asassessedbyabnormaloralglucosetolerancetests
(OGTTs) results and higher levels of HbA1c [78]. Another
study done in the United States with a sample size of 150
healthy men reported that AHI and the degree of nocturnal
desaturation were associated with glucose intolerance and
insulin resistance independent of obesity [31].
Finally, concrete evidence came from the Sleep Heart
Health Study [47]. In a community sample of 2656 subjects,
the AHI and average oxygen saturation during sleep were
associated with elevated fasting and 2-hour glucose levels
during an oral glucose tolerance test. Sleep apnea severity
was also associated with the degree of insulin resistance
independentofBMIandwaistcircumference,amongstother
confounders.
Thus, there is a strong evidence which indicates that
OSA and the risk of type 2 diabetes are associated, but the
evidence supporting a role for OSA in the development of
type 2 diabetes is still fairly limited. The reverse direction
of causality (i.e., that diabetes may be a cause for breathingInternational Journal of Endocrinology 3
abnormalities during sleep) is also possible, as autonomic
neuropathy could indeed disturb the control of respiration.
Meslieretal.[79] studied 595 men who were referred to a
sleep laboratory for suspected OSA. The cross-sectional data
from polysomnography and 2-hour oral glucose tolerance
tests(OGTTs)revealedthatDMwaspresentin30.1%ofOSA
patients and 13.9% of nonapneic snorers.
Studies in humans at high altitude [80] have indicated
that sustained hypoxia adversely aﬀects glucose tolerance
and insulin sensitivity. Excessive daytime sleepiness (EDS)
is a frequent, but not universal, symptom in patients with
OSA [81] and recent evidence suggests that EDS may be an
independent risk factor for diabetes [82]. In this study, it was
hypothesized that EDS was associated with insulin resistance
in OSA (independent of obesity), and that continuous
positive airway pressure (CPAP) therapy improves both
conditions, and our results conﬁrm this hypothesis. The fact
that EDS is also a marker of blood pressure response to
CPAP therapy in patients with OSA [81–83] suggests that
EDSisapotentiallyrelevantclinicalmarkerofseveralclinical
manifestations of OSA.
Vgontzasetal.[19]suggestedthatinsulinresistancewasa
risk factor stronger than BMI and testosterone plasma levels
for OSA and daytime sleepiness in premenopausal women
suﬀering from polycystic ovarian syndrome. More recently,
Punjabi et al. [84] found in 150 healthy mildly obese men
that the severity of OSA correlated with levels of insulin
2 hours after an oral glucose load and reported a twofold
increaseininsulinresistanceinsubjectswithanAHI65,after
controllingforBMIandpercentbodyfat.Manzella et al. [75]
observed that in 185 subjects with OSA, after adjusting for
obesity, both AHI and minimum oxygen saturation were
independent determinants of insulin resistance (the degree
ofinsulinresistanceincreasedby0.5%foreverysinglehourly
increase in the AHI).
Ficker et al. [85] assessed the presence of OSA (AHI 610)
in a group of diabetic patients with and without diabetic
autonomic neuropathy (DAN). They found a prevalence
of Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
amounting to 26% in diabetics with DAN; whereas none
of the diabetics without DAN met the criteria for OSAHS.
Neumann et al. [77] demonstrated a close correlation
between nocturnal oxygen desaturation and the presence
of DAN in a population of diabetic patients. In humans,
as mentioned, several studies have shown increased sympa-
thetic nervous system activity and increased catecholamine
which in turn results in hyperinsulinemia [27, 72, 86–88].
Figure 1 illustrates the relationship between OSA, insulin
resistance, and DM.
5.OSA andEndocrine
It is reported that the morbidity of acromegaly, diabetes, and
thyroid disorders may, to a large extent, be ascribed to an
altered sleep function [89].
Hypoxia mediated enhanced activation of the sympa-
thoadrenergic system increasing plasma insulin despite the
glycemic level was demonstrated in a study by Elmarsy
et al. [48]. Sympathetic hyperactivity can inﬂuence glucose
homeostasis by increasing glycogen breakdown and gluco-
neogenesis. Further, predisposition toward metabolic dys-
function in sleep apnea may also occur through its eﬀects on
thehypothalmic-pituitary-adrenal (HPA)axis.Experimental
partial or total sleep deprivation has been shown to increase
plasma cortisol level by 37% and 45%, respectively [90].
OSA to insulin resistance in humans has not been fully
elucidated. Several plausible explanations can be proposed.
Leproult et al. [91] hypothesized that the pathway between
OSA and glucose intolerance was stimulation of the HPA
axis due to hypoxias and fragmented sleep and leading to an
increase in cortisol with corresponding hyperglycemia. For
example, physical inactivity (due to day time somnolence)
andsleepdeprivationmaybeimportantcontributingfactors.
OSA is also characterized by a proinﬂammatory state and
elevated cytokine levels (e.g., tumor necrosis factor-alpha)
which may lead to insulin resistance [52–54, 92]. TNF-α is
usually elevated in individuals with obesity-induced insulin
resistance.StudieshavesuggestedthatsubjectswithOSAhad
higher concentrations of IL-6 and TNF-α than obese subject
without OSA [93].
Insulinresistanceisalsocausedbyincreased lipolysisand
fatty acid availability [93–95]. OSA may act through this
mechanism by virtue of its association with central obesity
andsympatheticactivation[27].Sympatheticactivationrises
circulating free fatty acids via stimulation of lipolysis and
promotes insulin resistance [96].
Leptin, IL-6, and inﬂammatory mediators have also been
implicatedinthepathogenesisofinsulinresistanceandother
features of metabolic syndrome [97, 98] .T h e r eh a v eb e e n
several studies which have suggested an independent asso-
ciation of obstructive sleep apnea with several components
of metabolic syndrome, particularly insulin resistance and
abnormalities in lipid metabolism [14–17].
On the other hand, there is increasing evidence that
Non Insulin Dependent Diabetes Mellitus (NIDDM) and
OSA may be directly related throughout sleep disordered
breathing-(SDB-) induced insulin resistance. Indeed, sleep
fragmentation due to repetitive apneas may increase the
plasma catecholamine and cortisol levels. These counter reg-
ulatory hormones induce glycogenolysis, gluconeogenesis,
lipolysis with increased free fatty acid portal levels, and
glucagon secretion, thus predisposing to hyperinsulinemia.
However, other factors, including hypercarbia and recurrent
arousals from sleep, can also increase autonomic output
[27, 99, 100].
6.DiabetesandREMSleep
Blood glucose homeostasis is subject to tight control exerted
by the endocrine system [101]; nonetheless, both ultradian
factors and diﬀerent stages of sleep inﬂuence insulin secre-
tion, concentration, and resistance [102, 103].
Insulin resistance increases towards the middle of the
nightwithasubsequentdecrease;asnonrapideyemovement
(NREM) sleep is more frequent and longer in the ﬁrst half of
thenightandrapideyemovement(REM)sleepinthesecond
half of the night, sleep patterns may be implicated [104].
REM sleep is a physiologic and repetitive behavioral state4 International Journal of Endocrinology
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Figure 1: It illustrates the relationship of Obstructive Sleep Apnea and Diabetes.
in which high cerebral energy requirements correspond to a
sustained neuronal activity [105]. REM sleep is accompanied
by increased cerebral glucose utilization and cerebral blood
ﬂow [106, 107]. A decreased concentration of insulin and
glucagon has been observed in REM sleep [102].
The higher prevalence of diabetes in OSA patients
who have worse REM related respiratory events may be
related to the unique neuroendocrine aspects of REM sleep,
and their possible disruption as a consequence of sleep-
disordered breathing. A decreased concentration of insulin
and glucagon has been observed in REM sleep [108].
Hypoxemia is an important stimulus for altering autonomic
activity, with larger desaturation causing greater increase in
sympathetic activity [109, 110]. REM sleep is known to be
associated with increased sympathetic activity [111]. REM
sleep (and loss of muscle tone) triggers marked increases in
sympathetic-nerve activity involving muscle blood vessels.
REM-sleep twitches result in surges in blood pressure, and
despite evidence of increased vasoconstriction in animals,
we found a suppression of sympathetic-nerve activity in our
subjects[111].Thus,REMsleepis foundtobe associatednot
only with insulin resistance and diabetes but it also results
in hypoxaemia due to sympathetic hyperactivity as well as
a variable blood pressure surge which eventually increases
the severity of diabetes and its risks. The study by Surani
et al. [112] showed a very high prevalence of diabetes in
an unselected cohort of Hispanic patients with obstructive
sleepapneacomparedtoCaucasian.AREMapnea-hypopnea
index of >20 was signiﬁcantly associated with an increase
prevalence of diabetes in Hispanic population. The brain,
which constitutes 2% of body mass, depends entirely on
glucose metabolism and utilizes approximately 50% of
total body glucose [113]; it extracts about 10% of blood
glucose without the need of insulin to cross the blood-
brain barrier due to facilitated glucose transport [114]. In
numerous physiological respects, REM is a distinctive sleep
phase, with brain activation reﬂected by a 30% larger blood
ﬂow compared with quiet wakefulness, which relates to
augmented glucose consumption [115].
7. OSA Treatment (CPAP)and
InsulinResistance
The eﬀect of CPAP treatment on glucose metabolism has
been evaluated in multiple studies [93, 116–129]. Trenell
et al. reported that CPAP treatment for 2 days rapidly
improved the insulin sensitivity in nondiabetic patients and
theeﬀectofCPAPpersistedforapproximately3monthsafter
treatment [123].
Brooks et al. found that obese patients with DM often
complained of excessive daytime sleepiness, fatigue, and
tiredness. In their study, patients with OSA were treated
with CPAP. After four months of treatment, the insulin
responsiveness had signiﬁcantly improved [130]. Several
other studies about successful treatment of OSA with
CPAP have been shown to produce improvement in insulin
sensitivity [59, 110, 119, 121, 122, 130–132]. Interestingly,
most of the studies suggest that the lower the BMI, the
better response in the insulin sensitivity improvement after
CPAP treatment [59] .W h e nO S Ai st i m e l ya n dp r o p e r l y
treated the results seen are not only a decrease in daytime
excessive sleepiness, but also a decrease in cardiovascular
risk, and in improvement of insulin resistance [1, 22]. In
as t u d yb yB a b ue ta l .[ 122], subjects who used CPAP for
more than four hours per day had a signiﬁcant reduction
in HbA1c level. Recent studies have linked untreated sleep
disordered breathing to hypertension, insulin resistance,
coronarydisease,congestiveheartfailure,stroke,obesity,and
gastro esophageal reﬂux [59].
More recently, in a population-based sample, Lindberg
et al. [133] showed reductions in fasting insulin levels
and insulin resistance (estimated by HOMA) after 3 weeksInternational Journal of Endocrinology 5
of CPAP treatment in 28 men with OSA compared with
matched nonapneic (AHI, 10) control subjects followed
over the same time period without CPAP therapy. Czupry-
niak et al. [121] also suggested that in non-diabetic patients,
increased blood glucose was seen after one night of CPAP
therapy, with a tendency to higher fasting insulin and
insulin resistance after CPAP. This was felt to be secondary
to a CPAP-related increase in growth hormone. A few
studies reported decrease in visceral fat after CPAP use
[131] while another study found no change [134]. Three
independent preliminary studies presented in abstract form
have suggested a positive response to CPAP therapy with
improvements in insulin sensitivity [135], fasting, [136],
and nocturnal [137] glucose levels in both diabetic and
nondiabetic patients with OSA. However, the eﬀect of CPAP
therapy on metabolic syndrome is controversial. The author
feels that recent studies have increasingly been favoring the
role of CPAP therapy in enhancing insulin sensitivity. Several
studies are currently ongoing which we hope can help to
resolve the issue.
8. Conclusion
Diabetes MellitusandObstructiveSleepApneaareextremely
common medical conditions that are prevalent in our
population. There is mounting evidence which links sleep
deprivation, obesity, and sleep-related breathing to diabetes.
Studies have established the association of OSA with diabetes
as well as the importance of timely CPAP therapy in decreas-
ing the insulin resistance in patients. However, despite the
availability of convincing evidence and abundant cross-
sectional studies, there is clearly a substantial requirement
for a well-designed prospective study to clearly address these
issues in depth. It is imperative for physicians to have a
high degree of suspicion regarding the reciprocal prevalence
of diabetes mellitus and obstructive sleep apnea. Moreover,
there is lot to be done in educating Family physicians
regarding the association of OSA and diabetes.
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